Point72 Asset Management
FOLD

Point72 Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Point72 Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-300,000
Closed -$4.32M – 997
2017
Q4 		$4.32M Buy
+300,000
New +$4.12M 0.02% 625
2017
Q3 		– Sell
-1,050,000
Closed -$10.6M – 932
2017
Q2 		$10.6M Buy
+1,050,000
New +$8.45M 0.06% 375

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Point72 Asset Management's FOLD Position: Q1 2026 in Review

Point72 Asset Management reduced its Amicus Therapeutics (FOLD) stake by 97% in Q1 2026, selling an estimated $28.9M and leaving 54,677 shares worth $791K. The position accounts for ﹤0.01% of the portfolio, ranked #2900.

Point72 Asset Management first reported a position in FOLD in Q3 2014 and has held it in 29 quarters since. The position peaked at $87.9M in Q2 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Point72 Asset Management held 54,677 shares of Amicus Therapeutics worth $791K as of Q1 2026.
  • Point72 Asset Management sold 2,013,777 Amicus Therapeutics shares in Q1 2026, an estimated $28.9M.
  • Amicus Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2900 holding.
  • Point72 Asset Management first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 29 quarters since.
  • Point72 Asset Management's Amicus Therapeutics position peaked at $87.9M in Q2 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.